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Abstract
Background
Linezolid is increasingly important for multidrug-resistant tuberculosis (MDR-TB) treatment.
However, among children with MDR-TB, there are no linezolid pharmacokinetic data, and its
adverse effects have not yet been prospectively described. We characterised the pharma-
cokinetics, safety, and optimal dose of linezolid in children treated for MDR-TB.
Methods and findings
Children routinely treated for MDR-TB in 2 observational studies (2011–2015, 2016–2018)
conducted at a single site in Cape Town, South Africa, underwent intensive pharmacokinetic
sampling after either a single dose or multiple doses of linezolid (at steady state). Linezolid
pharmacokinetic parameters, and their relationships with covariates of interest, were
described using nonlinear mixed-effects modelling. Children receiving long-term linezolid as
a component of their routine treatment had regular clinical and laboratory monitoring.
Adverse events were assessed for severity and attribution to linezolid. The final population
pharmacokinetic model was used to derive optimal weight-banded doses resulting in expo-
sures in children approximating those in adults receiving once-daily linezolid 600 mg. Forty-
eight children were included (mean age 5.9 years; range 0.6 to 15.3); 31 received a single
dose of linezolid, and 17 received multiple doses. The final pharmacokinetic model con-
sisted of a one-compartment model characterised by clearance (CL) and volume (V) param-
eters that included allometric scaling to account for weight; no other evaluated covariates
contributed to the model. Linezolid exposures in this population were higher compared to
exposures in adults who had received a 600 mg once-daily dose. Consequently simulated,
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weight-banded once-daily optimal doses for children were lower than those currently used
for most weight bands. Ten of 17 children who were followed long term had a linezolid-
related adverse event, including 5 with a grade 3 or 4 event, all anaemia. Adverse events
resulted in linezolid dose reductions in 4, temporary interruptions in 5, and permanent dis-
continuation in 4 children. Limitations of the study include the lack of very young children
(none below 6 months of age), the limited number who were HIV infected, and the modest
number of children contributing to long-term safety data.
Conclusions
Linezolid-related adverse effects were frequent and occasionally severe. Careful linezolid
safety monitoring is required. Compared to doses currently used in children in many settings
for MDR-TB treatment, lower doses may approximate current adult target exposures, might
result in fewer adverse events, and should therefore be evaluated.
Author summary
Why was this study done?
• Linezolid is an antibiotic that has recently been repurposed for the treatment of multi-
drug-resistant tuberculosis (MDR-TB).
• Based on emerging data from clinical trials, it is now recommended for inclusion as a
priority in treatment regimens for adults and children.
• There is a lack of evidence-based dosing guidelines for linezolid in children for MDR-
TB.
• Linezolid has frequent adverse effects that are associated with higher doses and longer
durations of treatment, but this has not been well described in children treated for
MDR-TB.
What did the researchers do and find?
• We assessed linezolid pharmacokinetics (concentrations) and safety among children
routinely treated for MDR-TB from 2 observational studies.
• We modelled this pharmacokinetic data and simulated the doses in children that would
be needed to achieve current targets.
• Doses supported by our data for some weight bands were lower than currently in use,
which may reduce the risk of adverse effects.
• Linezolid-related adverse effects were frequent—with low haemoglobin being the most
common—and occasionally severe (grade 3 or 4).
Linezolid PK and safety in children with MDR-TB
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What do these findings mean?
• Revised linezolid doses supported by this study now provide an evidence base for inter-
national dosing recommendations.
• All linezolid-treated children with MDR-TB should have careful safety monitoring to
include at least regular haemoglobin monitoring.
• Larger studies, evaluating the revised dosing, are needed to better characterise linezolid
safety and to assess the risk of more rare linezolid-related events, especially given the
small number of children in this study.
Introduction
Multidrug-resistant (MDR) tuberculosis (TB) continues to threaten global TB control, with an
estimated 460,000 incident cases worldwide in 2017 [1]. Treatment options remain limited.
Linezolid, an oxazolidinone antibiotic that binds to the 50S ribosomal subunit inhibiting pro-
tein synthesis [2], is increasingly being used for MDR-TB treatment. In routine use in adults
with MDR-TB, linezolid has been associated with good outcomes, with 68% and 82% of
patients successfully treated in 2 systematic reviews [3, 4]. In a recent systematic review and
individual patient data meta-analysis of 12,030 patients with MDR-TB, treatment with linezo-
lid was significantly associated with treatment success compared to failure or relapse, and also
with reduced mortality [5]. The World Health Organisation (WHO) released updated guid-
ance of MDR-TB treatment in 2018, which now classifies linezolid as a Group A drug, mean-
ing that it is a priority to include in individually constructed MDR-TB regimens for adults and
children [6].
Interest in linezolid has grown further based on the preliminary results of the Nix-TB trial
(NCT02333799), a single-arm open-label phase III study that evaluated very difficult to treat
adults with extensively drug-resistant (XDR)-TB or MDR-TB treatment intolerance, or failure,
with a three-drug regimen of bedaquiline, pretomanid, and linezolid (1,200 mg given once
daily) for 6 months [7]. In an interim analysis of the first 75 patients, 6 died, and all the
remaining patients completed the 6 months of treatment; 66 (88%) had durable cure 6 months
later, and there were only 2 relapses [7]. Linezolid is also a component of multiple other novel,
shortened MDR-TB treatment regimens currently under evaluation in adults [8].
Used in short courses (<28 days), linezolid is safe and well tolerated, but with the longer
treatment durations being used for MDR-TB treatment (typically 6 months or longer), it is
associated with frequent serious, dose- and duration-dependent adverse effects, including
anaemia, neutropaenia, thrombocytopaenia, peripheral neuropathy, and more rarely, optic
neuropathy, lactic acidosis, pancreatitis, and rhabdomyolysis [9]. In the systematic reviews of
linezolid-treated adults with MDR-TB, linezolid-related adverse effects were reported in 61%
and 59% of patients, respectively [3, 4], with 69% of these requiring linezolid dose adjustment
or discontinuation in one review [3]. A linezolid dose of>600 mg daily was associated with an
increased risk of adverse effects in these reviews [3, 4]. In early interim analysis of the Nix-TB
study, 27% of participants experienced a serious adverse event, and 71% of participants had at
least one linezolid-related treatment interruption, due mostly to myelosuppression or periph-
eral neuropathy [10].
There is a substantial burden of MDR-TB in children, with an estimated 25,000 to 32,000
incident cases globally each year [11, 12], many of whom could benefit from linezolid
Linezolid PK and safety in children with MDR-TB
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treatment. The evidence base for linezolid use in children with MDR-TB is currently limited.
A 2014 review of the literature identified only case reports and small case series that described
18 linezolid-treated children with MDR-TB [9]. As in adults, treatment outcomes were good,
with 15 of 18 children (83%) successfully treated, but 9 (50%) experienced a linezolid-related
adverse effect, 5 (28%) required dose adjustment, and 2 (11%) discontinued linezolid [9].
These limited early data were retrospective and had variable reporting of key information.
High-quality prospective data are needed to better characterise the incidence, severity, and
timing of adverse events among children with MDR-TB receiving long-term linezolid (>28
days of treatment).
The optimal dose of linezolid for treatment of adults with MDR-TB is not yet defined.
However, 600 mg once daily is currently the most frequently used routine dose in adults. The
dose of linezolid in children needed to approximate target exposures in adults with MDR-TB
receiving a 600 mg daily dose has not yet been characterised. Linezolid is well absorbed after
oral administration, with bioavailability of nearly 100% [2, 13]. Linezolid has a complex metab-
olism, with the primary metabolite formed through a nonenzymatic mechanism and the
major pathway of elimination urinary excretion [13]. Linezolid has good penetration into tis-
sues, including cerebrospinal fluid (CSF), where its exposure is 70% to 98% of plasma exposure
[13–15]. Studies of linezolid pharmacokinetics in adults to date have shown substantial vari-
ability between patients, patient populations, and studies, with limited data in patients with TB
[16–18].
Linezolid pharmacokinetics has been studied in children with gram-positive infections
[19]; however, there are no data in children treated for TB. This gap is important, because dos-
ing guidance should ideally be based on data from the target population, particularly as linezo-
lid pharmacokinetics is known to vary considerably across disease states [18]. Understanding
the optimal dose of linezolid for MDR-TB treatment in children is critical, because too high a
dose may increase the risk of serious adverse effects, while underdosing may reduce the effi-
cacy of this drug and may potentially lead to the development of linezolid resistance [20, 21].
Practical, weight-banded paediatric dosing guidance for linezolid based on its pharmacokinet-
ics in children with TB is urgently needed as its use is likely to increase substantially based on
the revised 2018 WHO guidance.
The objective of this study was to characterise the pharmacokinetics and safety of linezolid
in children routinely treated for MDR-TB and to estimate optimal weight-banded doses that
achieve adult target exposures for MDR-TB treatment.
Methods
Study design, setting, and population
The data described here are combined from 2 prospective observational pharmacokinetic
studies in Cape Town, South Africa, which used standard clinical study measures, identical
drug formulations, and standard sample collection and laboratory methods. The first observa-
tional study (MDRPK1) enrolled HIV-infected and -uninfected children 0 to<15 years of age
(n = 173) routinely treated with second-line anti-TB drugs for probable or confirmed drug-
resistant TB, who were followed until the end of MDR-TB treatment, from 2011 to 2015. All
children from this cohort routinely treated with linezolid were included in the current analysis.
The second study (MDRPK2) was a direct follow-up observational study to MDRPK1 and
enrolled HIV-infected and -uninfected children 0 to<18 years of age (n = 64) routinely
treated for MDR-TB with levofloxacin, moxifloxacin, or linezolid, in the same setting, from
2016. Follow-up for MDRPK2 is ongoing. In MDRPK2, children not prescribed linezolid as a
component of their routine MDR-TB care received a single dose of linezolid on the day of
Linezolid PK and safety in children with MDR-TB
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pharmacokinetic sampling and therefore contributed data to pharmacokinetic analyses but
not to long-term safety data. The total sample size for MDRPK2 was estimated from clinical
trial simulations with existing models to ensure sufficient precision primarily of the pharmaco-
kinetic parameter estimates (relative standard error [RSE] of parameter estimates of<10%)
(see S1 Text). The minimum overall sample size identified was 80 evaluable participants, with
100 participants being the maximum targeted sample size to allow for attrition. The present
report is based on a planned interim analysis after enrolment of 50 participants; 9 patients
from MDRPK1 were added to supplement participants from MDRPK2. The timing of this
analysis (which included just under the planned 50 participants) was also influenced by the
lack of a strong evidence base for linezolid dosing for TB in children and the urgent need for
data, as well as the timing of the revision of WHO MDR-TB treatment guidelines and the need
to inform that process in the absence of other paediatric data.
Children with MDR-TB were treated individually according to national and international
guidelines—with a minimum of 4 confirmed- or likely-effective drugs, usually with the addi-
tion of pyrazinamide and ethambutol—generally for 12 to 18 months’ duration [22–24]. Due
to its cost and adverse effects, at the time of the study, linezolid was reserved for children with
MDR-TB with (1) probable or confirmed additional fluoroquinolone resistance, including
those with XDR-TB; (2) MDR-TB meningitis; (3) or documented intolerance to other second-
line anti-TB medications. Management of linezolid-associated adverse effects was individual-
ised depending on the event type and severity, the child’s TB disease severity, and the availabil-
ity of other treatment options. For common, nonsevere events such as low-grade (grades 1 or
2) anaemia, linezolid would typically be temporarily interrupted and then restarted at half the
dose. For more severe events (grade 3 or 4), linezolid may have been permanently discontin-
ued, depending on other treatment options and the child’s clinical status at the time. These
clinical decisions were individualised and were made at the discretion of the routine treating
clinician.
Linezolid dosing and pharmacokinetic sampling
At the time of the study, there was no dosing recommendation based on high-quality evidence
for linezolid for TB treatment in children. The routinely prescribed dose of linezolid in the
study setting, based on expert opinion, was 10 mg/kg/dose twice daily (20 mg/kg daily) for
children <10 years of age and 10 mg/kg/dose once daily for children >10 years of age, up to a
maximum total daily dose of 600 mg. This was based on an approximation of the dose required
to achieve similar exposure as in adults receiving 600 mg once daily, based on existing pharma-
cokinetic data from children with non-TB infections [9]. Linezolid was available as 600 mg
unscored tablets and as a 20 mg/mL suspension (Pfizer, Sandton, South Africa).
In the MDRPK1 study, an exact 10 mg/kg dose was prepared and administered along with
other anti-TB medications in the regimen on the day of pharmacokinetic sampling. Samples
were drawn just prior to—and then at 1, 2, 4, 8, and either 6 or 11 hours after—the anti-TB
medications’ dose. In MDRPK2, a weight-banded dose (approximately 10 mg/kg) was admin-
istered on pharmacokinetic sampling days along with other routine anti-TB medications in
the regimen. Samples were drawn just prior to, and at 1, 4, and 10 hours after, the observed
dose. For both studies, medications were administered identically, on an empty stomach after
an overnight fast, and were given either as whole tablets if the child was able to swallow, as a
suspension if available, or as crushed tablets mixed in a small amount of water if the child was
unable to swallow and the suspension was unavailable (due to occasional stockout), using
identical formulations in both studies. On occasion, all anti-TB medications were adminis-
tered via nasogastric tube on pharmacokinetic sampling days, only if the child refused to
Linezolid PK and safety in children with MDR-TB
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002789 April 30, 2019 5 / 20
swallow medications orally (e.g., young children). One hour after the anti-TB medication
dose, antiretroviral medications were administered in HIV-infected children, and a standard
breakfast was offered.
Laboratory assays
Pharmacological assays were performed at the University of Cape Town, Division of Clinical
Pharmacology using a validated liquid chromatography tandem mass spectrometry (LC MS/
MS) method. This LC MS/MS method involves a simple protein precipitation extraction using
20 μl plasma, followed by isocratic separation on a Poroshell 120EC-C18, 4.6 × 50 mm, 2.7 μm
column. A deuterated internal standard, Linezolid-d3, is used to monitor the method across a
calibration range of 0.100 μg/ml (LLOQ) to 30 μg/ml (ULOQ). The method performed well
over the period of analysis, with an accuracy ranging from 96.6% to 98.7% and a precision esti-
mate of less than 7.2% (% CV) over all 3 quality control (QC) sample concentrations (QC low
at 0.25 μg/ml, QC medium at 12 μg/ml, and QC high at 24 μg/ml).
Safety
All children had regular clinical and laboratory safety assessments, including a full blood
count monthly for the first 6 months, then every 2 months or as clinically indicated until com-
pletion of treatment. All adverse events were recorded and were assessed for attribution to
linezolid based on the judgment of the investigator or subinvestigator, who was not blinded to
the presence or duration of linezolid treatment, and graded for severity. In MDRPK1, events
were graded according to standard Division of AIDS (DAIDS) criteria (“DAIDS Table for
Grading the Severity of Adult and Pediatric Adverse Events” version 1.0, December 2004,
updated August 2009) [25]. In MDRPK2, events were graded according to the updated DAIDS
Table for Grading the Severity of Adult and Pediatric Adverse Events (version 2.0, November
2014 [26]; corrected version 2.1, July 2017 [27]). There were no differences between these ver-
sions for most of the adverse events that are relevant to linezolid, including low platelets, low
white blood cell count, and peripheral neuropathy; the grading for these events is shown in S1
Table. There were slight differences in the way low haemoglobins were graded, which are sum-
marised separately in S2 Table. The minor differences in low haemoglobin grading are unlikely
to have meaningfully changed the results or the study’s overall conclusions.
Statistical analysis
The full MDRPK2 study protocol Statistical Considerations section is included as S1 Text. The
analyses described here and in the following section are consistent with the general statistical
approach in the protocol. Baseline characteristics were presented with descriptive statistics.
Weight-for-age (WAZ) and height-for-age (HAZ) z-scores were calculated using British refer-
ence values, as WHO references only include children <10 years of age [28]. Only children
receiving linezolid as a component of their routine drug-resistant TB treatment regimen were
included in safety analyses (i.e., not children only receiving single-dose linezolid). Adverse
events at least possibly related to linezolid were presented by grade, and the rate of events per
person-time of observation were calculated. The development of a pharmacokinetic-pharma-
codynamic model to assess the relationship between linezolid exposures and adverse events
was planned after the study was fully enrolled and completed. At the time of the current analy-
sis, this was explored using the analyses described below. The median (interquartile range
[IQR]) linezolid area under the concentration time curve from 0 to 24 hours at steady state
(AUC0–24ss) was reported and compared by the presence of linezolid-related adverse effects
using the Wilcoxon rank sum test. Linezolid exposure was further defined using AUC0–24ss
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and split into 2 groups using the median AUC0–24ss, 107 mg/L × h. Survival curves for time to
any linezolid-related adverse effect and time to grade 3 or 4 linezolid-related adverse effects
were displayed using Kaplan-Meier plots. Patients were censored at the time of the relevant
linezolid-related event or when linezolid was discontinued. The log-rank test was used to
assess whether linezolid exposure was associated with the time to linezolid-related grade 3/4 or
any-grade adverse events. If the proportional hazards assumption was violated, log-rank test
was reported along with a comparison of the restricted mean survival times (RMSTs) [29, 30].
During the peer review process, these analyses were repeated to assess associations between
the minimum linezolid concentrations (Cmins) and linezolid-related adverse effects. A linezolid
Cmin of 2 mg/L, suggested as a threshold value for risk of adverse events [31], was used to sepa-
rate groups in survival curves.
Population pharmacokinetic model and dosing simulations
Pharmacokinetic data were characterised based on a population nonlinear mixed-effects
modelling approach using the software NONMEM 7.41 (ICON Development Solutions, Elli-
cott City, Maryland). The method of estimation used was the first order conditional estimation
(FOCE) method with the option ‘interaction’. Between-subject variability (BSV) was modelled
exponentially, and the residual error was described using a combination of an additive and
proportional error model. Inter-occasion and inter-cohort variability were also evaluated to
deal with the differences between both studies and pharmacokinetic occasions. Model building
was performed in 2 stages, with the structural model developed first and the covariate analysis
done subsequently. The main covariates evaluated in the analysis were weight, height, age, sex,
race, HIV status, linezolid administration method (oral versus nasogastric tube), formulation
(whole versus crushed versus suspension), linezolid given as single dose versus at steady state,
and interactions with concomitant drugs. Covariate identification was done using the stepwise
covariate modelling (SCM) through the PsN software (version 4.6.0). This method consists of
the stepwise testing of linear and nonlinear covariate-parameter relationships with forward
inclusion and backward exclusion approaches with significance levels of 0.05 and 0.01, respec-
tively. Given the modest sample size and the large number of covariates, the analysis was also
done with a forward inclusion level of 0.2 and backward exclusion of 0.05. The final inclusion
of the identified significant covariates was done taking into account scientific plausibility, sta-
tistical significance, and clinical relevance. Both stages of model building were evaluated by the
likelihood ratio test, goodness of fit plots, and visual predictive checks (VPCs). R software (ver-
sion 3.5.1) was used to make the graphical representation, using the xpose package (version
4.6.1) (reference: https://CRAN.R-project.org/package=xpose) for data set checkout and
graphical evaluation of the results.
The final model was used to simulate different linezolid doses depending on children’s
weights. Model-identified optimal doses were derived based on the following assumptions
with respect to formulation availability: (a) independent of formulation, e.g., exact optimal
doses, (b) optimal doses with 20 mg/mL suspension, and (c) optimal doses with 600 mg tablet
in one-fourth tablet increments. The target linezolid exposure used for dosing simulations was
the AUC0–24ss in adults with TB after a 600 mg once-daily dose (110 mg/L
.h). This target is
based on data on linezolid pharmacokinetics from a completed phase II dose-ranging trial in
adults with drug-susceptible TB (LINCL-001, NCT02279875, N = 99) and an ongoing phase
III trial in adults with MDR-TB, (NiX-TB, NCT02333799, N = 88) (S4 Table). Two hundred
simulations of the pharmacokinetic profile of a paediatric population with weights ranging
from 5 to 56 kg, receiving the calculated weight-banded dose regimen, were performed in
NONMEM (Icon Development Solutions, Ellicot City, MD), and their AUCs were reported.
Linezolid PK and safety in children with MDR-TB
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This study is reported as per the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) guideline (S1 STROBE Checklist).
Ethical considerations
Written informed consent was provided by the parent(s) or legal guardians, and written
informed assent was given by participants�7 years of age. Ethical approval for the study was
provided by the Health Research Ethics Committee of Stellenbosch University (N11/03/059
for MDRPK1 and N15/02/012 for MDRPK2).
Results
Study population
Forty-eight children were included in the present analysis, 9 from MDRPK1 and 39 from
MDRPK2. Baseline clinical and demographic characteristics by study (MDRPK1, MDRPK2)
are shown in Table 1.
Pharmacokinetic model
Of the 48 children included, 5 participants contributed data from more than 1 pharmacoki-
netic sampling occasion. Four patients from MDRPK2 contributed full profiles from 2 sam-
pling occasions, and 1 patient from MDRPK1 contributed 1 full profile and 2 partial profiles.
The pharmacokinetic profiles of these 5 children are displayed in S1 Fig, including the raw
pharmacokinetic data, their individual prediction, and the dose and formulation received on
each occasion. No concentrations were below the limit of quantitation. The final pharmacoki-
netic model consisted of a one-compartment disposition model characterised by clearance
(CL) and volume (V) parameters. CL and V included allometric scaling, using the exponents
0.75 and 1, respectively, to account for changes in weight. The rate of absorption (Ka) was
Table 1. Baseline demographic and clinical characteristics of children with MDR-TB receiving linezolid including data from 2 observational pharmacokinetic
studies.
Characteristic MDRPK1 Multiple dose� (n = 9) MDRPK2 Multiple dose (n = 8) MDRPK2 Single dose (n = 31) Combined (n = 48)
Median age in years (range) 4.8 (0.6–13.8) 4.9 (1.8–15.3) 4.4 (1.1–14.6) 4.6 (0.6–15.3)
Male gender (%) 6 (66.7) 6 (75.0) 12 (38.7) 24 (50.0)
Ethnicity (%)
Black 4 (44.4) 6 (75.0) 15 (48.4) 25 (52.1)
Mixed race 5 (55.6) 2 (25.0) 16 (51.6) 23 (47.9)
HIV-infected (%) 1 (11.1) 1 (12.5) 1 (3.2) 3 (6.3)
WAZ < −2 (%) 3 (33.3) 3 (37.5) 3 (9.7) 9 (18.8)
Administration on day of PK sampling
NGT (%) 6 (66.7) 0 (0.0) 6 (19.4) 12 (25.0)
Oral (%) 3 (33.3) 8 (100.0) 25 (80.6) 36 (75.0)
Formulation
Whole tablet (%) 1 (11.1) 3 (37.5) 1 (3.2) 5 (10.4)
Crushed tablet (%) 1 (11.1) 1 (12.5) 8 (25.8) 10 (20.8)
Suspension (%) 7 (77.8) 4 (50.0) 22 (71.0) 33 (68.8)
�None of the MDRPK1 patients had single dose.
The median age (range) of the children receiving each type of formulation are 13.0 years (7.2–15.3) for whole tablet (n = 5), 12.3 years (2.7–15.4) for crushed tablet
(n = 12), and 2.6 years (0.6–9.6) for suspension (n = 37).
Abbreviations: MDR-TB, multidrug-resistant tuberculosis; NGT, nasogastric tube; PK, pharmacokinetic; WAZ, weight-for-age z-score.
https://doi.org/10.1371/journal.pmed.1002789.t001
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constrained to be faster than the rate of elimination (CL/V) in order to avoid flip-flop kinetics
during model estimation [32]. BSV was estimated on both CL and V. Inter-occasion and inter-
cohort variability were assessed and were not included in the final model due to the lack of sig-
nificance. This lack of significance may be explained by the small number of pharmacokinetic
measurements available at second and third occasions (only 5 out of 48 children). Similarly,
the lack of significance when using inter-cohort variability suggests that the populations
between cohorts were similar and comparable. No other covariates tested—including age, HIV
status, formulation (whole tablets versus crushed tablets versus suspension), WAZ, HAZ, body
mass index, administration by nasogastric tube—significantly improved the model fit for any
of the pharmacokinetic parameters after accounting for the effect of weight. S3 Table reports
the coefficients and the 95% confidence intervals of several covariate models tested during the
covariate analysis. Table 2 describes the final model parameters. The final model fit the
observed data well, as shown in the VPC (Fig 1). Calculated AUC and maximum plasma con-
centrations from our study population are described in Table 3.
Simulated exposures
The proposed weight-banded doses across weights that approximated the emerging AUC tar-
gets reported in adults with MDR-TB receiving a 600 mg once-daily dose are shown in
Table 4. The expected linezolid exposures (AUC0–24ss) across weights from simulations using
the final model and this weight-banded dosing strategy are shown in Fig 2.
Safety
Seventeen children were included in the safety analysis (median age 4.7 years; range 0.6 to
15.3) and followed for a median duration of 17.7 months on linezolid (IQR 7.5 to 19.7). Ten
patients (59%) experienced at least 1 adverse event possibly attributed to linezolid, the most
frequent being low haemoglobin, with 12 events in 10 patients (Table 5). There were three
grade 3 and two grade 4 events in 5 (23%) participants, all anaemia. The linezolid dose was
adjusted after 4 (23.5%) events; linezolid was temporarily interrupted and restarted after 5
(29.4%) events, and 4 (23.5%) participants permanently discontinued linezolid due to adverse
events. For the single episode of peripheral neuropathy, which occurred in a 13-year-old
female, linezolid was temporarily interrupted, and the patient was treated with gabapentin,
resulting in symptomatic improvement. The linezolid was restarted at a lower dose after symp-
toms resolved with no sequelae, and symptoms did not recur at the lower dose. We did not
identify any events of optic neuropathy.
Table 2. Parameter values for modelled linezolid pharmacokinetics in children with MDR-TB (n = 48).
Parameter Estimate RSE (%)
Ka (h
−1) θ_Ka + (CL/V) θ_Ka = 0.77 25
CL/F (L/h) = θ_CL ×〖"(WT� 70")〗^0.75 θ_CL = 4.73 8
V/F (L) = θ_V × (“WT � 70”) θ_V = 54.8 8
BSVCL/F (%) 37 16
BSVV/F (%) 32 23
Additive error (mg/L) 0.78 91
Proportional error (%) 25 30
Abbreviations: BSV, between-subject variability; CL, clearance; F, bioavailability; Ka, absorption rate constant; RSE,
relative standard error; V, volume of distribution; WT, weight in kg; θ, typical parameter.
https://doi.org/10.1371/journal.pmed.1002789.t002
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The median linezolid exposure was associated with occurrence of a grade 3 or 4 linezolid-
related adverse event (p = 0.020) but not with occurrence of any grade linezolid-related adverse
event (p = 1.000) (Table 6). The Cmin and AUC were highly correlated (pairwise correlation
Fig 1. VPC corresponding to final linezolid pharmacokinetic model. Dots represent the observed linezolid concentrations; the solid lines
correspond to the 5th, 50th, and 95th percentiles of these observations. Shaded areas are the model-predicted 95% confidence intervals for the
median (blue), and 5th and 95th (grey) percentiles obtained from 500 simulated data sets. VPC, visual predictive check.
https://doi.org/10.1371/journal.pmed.1002789.g001
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coefficient = 0.7737, p = 0.0003). The median linezolid Cmin was not significantly associated with
either any grade (p = 0.696) or with a grade 3 or 4 (p = 0.206) linezolid-related adverse event.
For children with an adverse event, the median (IQR) time to any linezolid-related adverse
event was 3.2 months (1.8 to 13.9) (n = 10), and time to grade 3 or 4 linezolid-related adverse
event was 2.4 months (1.8 to 4.7) (n = 5). The Kaplan-Meier survival curves for time to linezo-
lid-related adverse events are displayed in Fig 3. The time to grade 3 or 4 linezolid-related
adverse event differed by linezolid exposure (log-rank p = 0.0121), but not the time to any line-
zolid-related adverse event (log-rank p = 0.5895, RMST p = 0.344) (Fig 4). Because there was
crossing of the survival curves for time to any grade linezolid-related adverse event by linezolid
exposure (Fig 4A), we censored the curve at 360 days, but there was still no difference (log-
rank p = 0.360). Kaplan-Meier survival curves for time to linezolid-related adverse events by
Cmins are shown in S2 Fig. There were no differences by linezolid Cmin in time to any grade
(log-rank p = 0.9267) or grade 3 or 4 (log-rank p = 0.5694) linezolid-related adverse event.
Discussion
This study provides data on linezolid pharmacokinetics in children with TB to inform evi-
dence-based dosing. Linezolid-related adverse events were frequent and occasionally of high
grade (grade 3 or 4) in children treated long term for MDR-TB.
Table 3. Calculated linezolid AUC0–24ss and Cmax from children with MDR-TB (n = 48) stratified by age and daily dose.
Age Dose Number of children AUC0–24SS (mg/L
.h) Cmax (mg/L)
Median [Min–Max] Median [Min–Max]
<10 mg/kg 16 78.5 56.63–158.09 7.35 5.49–9.16
<10 years 10 to <20 mg/kg 16 127.52 59.23–243.23 10.1 6.95–15.8
�20 mg/kg 5 189.8 139.3–215.9 11.193 9.36–14.1
<10 mg/kg 7 98.9 75.27–321.90 7.306 5.10–21.2
�10 years 10–20 mg/kg 4 113.7 102.2–271 11.175 9.87–19.5
�20 mg/kg 0 - - - -
Abbreviations: AUC0–24ss, area under the concentration time curve from 0–24 hours at steady state; Cmax, maximum plasma concentration; MDR-TB, multidrug-
resistant tuberculosis.
https://doi.org/10.1371/journal.pmed.1002789.t003
Table 4. Proposed weight-banded once-daily doses of linezolid for children treated for MDR-TB approximating the exposure in adults receiving a 600 mg once-
daily dose (AUC0–24ss 110 mg
.h/L).
Formulation-independent optimal dosage� 20 mg/mL suspension 600 mg tablet#
Weight band
(kg)
Optimal mg dose,
once daily
Dose range for weight
band (mg/kg)
Optimal mg dose,
once daily
Dose range for weight
band (mg/kg)
Optimal mg dose,
once daily
Dose range for weight
band (mg/kg)
5 to <7 80 11.4–16.0 80 (4 mL) 11.4–16.0 150 alt days (1/4 tab) —
7 to <10 120 12.0–17.1 120 (6 mL) 12.0–17.1 150 (1/4 tab) 15.0–21.4
10 to <16 150 9.4–15.0 160 (8 mL) 10.0–16.0 150 (1/4 tab) 9.4–15.0
16 to <24 220 9.2–13.8 — — 300 (1/2 tab) 12.5–18.8
24 to <31 280 9.0–11.7 — — 300 (1/2 tab) 9.7–12.5
31 to <35 300 8.6–9.7 — — 300 (1/2 tab) 8.6–9.7
35 to <44 400 9.1–11.4 — — 450 (3/4 tab) 10.2–12.9
>44 600 13.6 - — — 600 (1 tab) 13.6 -
�These optimal doses were identified without considering formulation strength.
#Possible doses were constrained to 1/4, 1/2, and 3/4 tablet options.
Abbreviations: alt, alternate days; AUC0–24ss = area under the concentration time curve from 0–24 hours at steady state; MDR-TB, multidrug-resistant tuberculosis.
https://doi.org/10.1371/journal.pmed.1002789.t004
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The linezolid plasma AUCs seen in our cohort were higher than expected compared to pre-
viously published values in children (58 mg/L.h for children 3 months to 11 years of age, and
95 mg/L.h for 12 to 17 years of age following a 10 mg/kg dose) [19]. The previously published
paediatric data reported on single intravenous doses only, so direct comparison to our data is
challenging. In certain age groups, exposures in our paediatric cohort were even higher than
expected target exposure in adults. These differences could be related to previously unidenti-
fied drug-drug interactions with other anti-TB drugs. No association was found between any
pharmacokinetic parameters and concomitant drugs in our study; however, the study may
Fig 2. Simulated linezolid exposures in children with model-identified optimal doses. Simulated linezolid AUC0–24ss versus body weight using the linezolid
doses listed in Table 4 for (a) model-identified optimal doses independent of formulation, (b) optimal doses for the 20 mg/mL suspension, (c) optimal doses for
the 600 mg tablet administered in one-fourth tablet increments; the red hashed line indicates the adult target exposure (AUC0–24ss 110 mg/L
.h). AUC0–24ss, area
under the concentration time curve from 0 to 24 hours at steady state; LNZ, linezolid; Q2D, once every other day; QD, once daily.
https://doi.org/10.1371/journal.pmed.1002789.g002
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have been underpowered to detect these. Linezolid has complex metabolism, and as previously
noted, there is substantial variability in linezolid pharmacokinetics between individuals and by
disease state [17, 18, 33, 34]. Differences in bioavailability, including formulation effects,
should also be considered. The formulations used in our study were all nongeneric, as used in
most adult studies to date, and no differences were observed in pharmacokinetic parameters
by formulation administration (whole versus crushed versus suspension) in our cohort.
Our study combined linezolid pharmacokinetic data after both single and multiple doses.
Usually, pharmacokinetic parameters (CL, V of distribution, and absorption rate constant)
derived based on single-dose pharmacokinetic data can predict well multiple-dose pharmaco-
kinetics, if the pharmacokinetics are linear and there are no time-dependent trends, such as
autoinduction or nonlinear elimination. This was the case for linezolid. The multiple-dose
data confirmed the absence of these trends in this paediatric population, and the single-dose
data were valuable in informing the relationship between children’s CL and weight and/or age,
which forms the basis for establishing the dosing algorithm.
Additional data on linezolid pharmacokinetics in children treated for MDR-TB are impor-
tant to confirm all of these findings.
At the linezolid doses used in this study, 10 of 17 children treated long term experienced a
linezolid-related adverse event, all of whom had anaemia in addition to some other, less fre-
quent events. This is similar to adult data and to a previous summary of published case series
and case reports in which 9 of 18 children had a linezolid-related event [9]. In our study, regu-
lar monitoring was able to identify anaemia at mild grades in most children. The approach of
temporarily interrupting the linezolid until the haemoglobin had improved, followed by re-
introduction at a lower dose (usually half the previous dose), was generally well tolerated. Five
children experienced a grade 3 or 4 anaemia, 4 of whom permanently discontinued linezolid.
Although all patients recovered from their anaemia without sequelae, the frequency and sever-
ity of these events highlights the importance of careful monitoring of haematological parame-
ters during long-term linezolid treatment. In our study, once haemoglobin values began to
drop, they often fell rapidly, so the first signs of a falling haemoglobin should prompt more fre-
quent testing, and there should be a low threshold for temporarily interrupting doses,
Table 5. Adverse events, possibly, probably or definitely attributed to linezolid, in children treated for MDR-TB with linezolid (n = 17), by grade.
Adverse event No. of patients with event Grade 1 Grade 2 Grade 3 Grade 4 Total no. of events Event rate (per 100 person-years)
Peripheral neuropathy 1 1 0 0 0 1 4.8
Low haemoglobin 10 5 2 3 2 12 57.2
Low platelets 2 1 1 0 0 2 9.5
Low white blood cell count 1 1 0 0 0 1 4.8
Seventeen patients followed for a median time of 17.7 months (IQR: 7.5–19.7 months); total person-years = 21.0.
Abbreviations: IQR, interquartile range; MDR-TB, multidrug-resistant tuberculosis.
https://doi.org/10.1371/journal.pmed.1002789.t005
Table 6. Comparison of median linezolid AUC0–24ss by occurrence of linezolid-related adverse events in children with MDR-TB (n = 17).
Any grade linezolid-related adverse event Grade 3 or 4 linezolid-related adverse event
Adverse event (n = 5) No adverse event (n = 12) p-Value� Adverse event (n = 10) No Adverse event (n = 7) p-Value�
Median linezolid AUC0–24ss (IQR) 110 (81–229) 105 (83–139) 1.000 229 (121–249) 95 (79–117) 0.020
�Wilcoxon rank sum test
Abbreviations: AUC0–24ss, area under the concentration time curve from 0–24 hours at steady state; IQR, interquartile range; MDR-TB, multidrug-resistant
tuberculosis.
https://doi.org/10.1371/journal.pmed.1002789.t006
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depending on the importance of linezolid to the efficacy of the regimen. The cumulative inci-
dence of adverse events increased with longer duration of treatment; however, there were
events detected even in the first 60 days, including grade 3 and 4 events. Reducing the duration
of linezolid treatment would likely reduce, but not eliminate, the risk of adverse events, and
careful safety monitoring will be necessary in future clinical trials and in routine care, regard-
less of the duration of linezolid therapy. Reducing the linezolid dose would be expected to
reduce its activity and may increase the risk of acquired resistance. The risk to children, who
tend to have paucibacillary disease, would likely be low, especially when the child has already
been on treatment for weeks or more with effective companion drugs in the regimen, and the
bacillary burden would have been substantially reduced. However, there is still uncertainty
about the risk of acquired resistance and the efficacy of these lower doses of linezolid, and an
improved understanding of how to weigh up this risk versus benefit is an area for future
research.
Fig 3. Time to linezolid-related adverse events in children treated for MDR-TB. (a) Kaplan-Meier survival curve for time (in days) to an adverse event of any grade
at least possibly related to linezolid; (b) Kaplan-Meier survival curve for time (in days) to a grade 3 or 4 adverse event at least possibly related to linezolid. MDR-TB,
multidrug-resistant tuberculosis.
https://doi.org/10.1371/journal.pmed.1002789.g003
Fig 4. Time to linezolid-related adverse events by linezolid exposures in children treated for MDR-TB. (a) Kaplan-
Meier survival curves for time to first linezolid-related adverse event of any grade by linezolid-related AUC0–24ss < 107
mg/L�h versus AUC0–24ss < 107 mg/L
�h (log-rank p = 0.5895); over a 450-day follow-up, the RMST was not significantly
different by AUC0–24ss (295 days if AUC0–24ss < 107 mg/L
�h; 222 if AUC0–24ss > 107 mg/L
�h [p = 0.344]). (b) Kaplan-
Meier survival curves for time to grade 3 or 4 linezolid-related adverse event by linezolid-related AUC0–24ss <
versus> 107 mg/L�h; log-rank p = 0.0121. AUC0–24ss = steady state area under the concentration time curve from 0–24
hours; MDR-TB, multidrug-resistant tuberculosis; RMST, restricted mean survival time.
https://doi.org/10.1371/journal.pmed.1002789.g004
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Grade 3 or 4 events were strongly associated with higher linezolid exposures. The lower
doses we have proposed may reduce this risk. Therapeutic drug monitoring may also be a con-
sideration to explore further to reduce the risk of these more severe events.
Peripheral neuropathy was detected in only one child, a 13-year-old female, and improved
with temporary discontinuation of linezolid and gabapentin treatment, and it ultimately
resolved without sequelae after recommencing a reduced linezolid dose. To our knowledge,
there is no reason to believe that children do not develop linezolid-related peripheral neuropa-
thy, although the risk may be lower than in adults. Peripheral neuropathy presents with symp-
toms of pain, numbness, and tingling in a stocking-glove distribution, and signs of weakness,
reduced deep-tendon reflexes, and loss of sensation of vibration, proprioception, and tempera-
ture. All of these signs and symptoms can be challenging to elicit in young children. To our
knowledge, there are no validated clinical approaches for screening for peripheral neuropathy
that can be used in young children. The gold standard for diagnosis is nerve conduction stud-
ies, which are invasive and specialised tests not widely available in high–TB-burden settings.
The implication is that peripheral neuropathy may be difficult to identify in young children,
and thus there is a risk of underdiagnosis. This is an important consideration when weighing
the risk to benefit for the use of linezolid in children with MDR-TB. We did not identify any
other serious, more rare events such as optic neuropathy or lactic acidosis. This is reassuring
but should be interpreted cautiously, as the number of children included here is modest, and
formal ophthalmologic examinations were not done. Lactate levels and pancreatic enzymes
were not monitored, which is also a limitation. However, in no children were clinical symp-
toms or signs suggestive of optic neuropathy, lactic acidosis, or pancreatitis reported or
suspected.
Using the final model, our simulations identified weight-banded doses that would achieve
the proposed target exposure, based on emerging data in adults with MDR-TB receiving a 600
mg daily dose (Table 4, Fig 2). Doses used for children in routine care will be constrained by
available formulations. A 20 mg/mL suspension exists but is not widely available due to cost,
variable supply, or lack of in-country registrations, and most settings only have access to the
unscored 600 mg tablet. Pragmatic doses using the available formulations result in less optimal
exposures in some weight bands, which may increase the risk of adverse effects (Table 4, Fig
2). This should not limit the use of linezolid in children when indicated; however, more flexi-
ble, child-friendly formulations are urgently needed.
These new proposed doses are lower than those used in this study and are currently used in
routine care for MDR-TB in most settings. Lower doses in children would likely reduce the
risk of adverse events, which were frequent in this cohort, although this would need to be con-
firmed in further studies. Because exposures with these doses in children would be expected to
approximate those in adults after a 600 mg daily dose, the efficacy would be expected to be as
good or better in most children compared to adults receiving this dose, as children often have
paucibacillary TB. Careful evaluation of the pharmacokinetics, safety, and treatment outcomes
in children treated with these proposed new, weight-banded doses of linezolid is needed.
The linezolid exposure targeted clearly has an impact on paediatric dosing studies and rec-
ommendations. The target exposure chosen here (110 mg/L.h) is based on robust data from 2
adult TB trials. This target was chosen because it was taken from recent studies that also
included efficacy and toxicity data. The optimal linezolid target exposure and the optimal dos-
ing strategy for linezolid has not yet been established in adults. An ongoing phase III trial
(ZeNix, NCT03086486) is evaluating the efficacy and safety of multiple doses and durations of
linezolid in combination with bedaquiline and pretomanid in adults with MDR-TB. ZeNix
will provide important data to inform future linezolid dosing recommendations in adults. A
free AUC/minimum inhibitory concentration (MIC) ratio of>100 has been proposed for
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efficacy based on hollow fibre model data [35, 36]. A linezolid free-AUC/MIC ratio of<96 or
a trough <2 mg/L have been proposed as targets to reduce the risk of adverse effects [31, 35,
36]. However, more data are needed to understand how clinically relevant these targets are in
adults and in children of different ages. We are planning additional work to better characterise
the relationship between linezolid pharmacokinetics and adverse events using current and
future data and pharmacokinetic-pharmacodynamic modelling. Due to its excellent penetra-
tion into CSF, linezolid may be an important component of treatment regimens for TB menin-
gitis. Higher doses of linezolid than used for other forms of TB may be needed in order to
achieve target exposures in CSF. This is an important area for future research.
There is a growing awareness of the importance of drug exposure at the site of disease,
which is influenced by penetration of drugs into different areas of TB lesions [37]. Targeting
plasma AUC/MIC does not take this key aspect into consideration. Targeting drug exposures
that are linked with efficacy in TB patients with the spectrum of TB disease and lung pathology
does incorporate this aspect and, in our estimation, is a more appropriate target given the cur-
rent state of knowledge. Regardless, paediatric linezolid dosing recommendations may need to
evolve as additional data on optimal dosing in adults become available.
The study has a number of important limitations. Although this is a relatively large study of
intensively sampled pharmacokinetics in children, the numbers of included children remain
small, especially regarding potentially relevant subgroups. There were few very young and
small children included in this analysis, and none under 6 months of age. There are data in
neonates and young infants indicating that the CL of linezolid is associated with postnatal age,
with children <8 days of age having lower CL than those 8 days to 12 weeks of age (i.e., CL
rapidly increased in the first week of life) [38]. Our proposed doses for smaller children should
be interpreted with caution because infants younger than 6 months were not included. For cli-
nicians in the field responsible for caring for the occasional young, small child with MDR-TB,
some practical guidance on dosing—even with inherent limitations—is, however, still valuable.
Additionally, there were few children with HIV infection or undernutrition. We are unaware
of clinically significant drug-drug interactions between antiretrovirals and linezolid or of other
previously described effects of HIV or undernutrition on linezolid pharmacokinetics. How-
ever, these are important covariates to consider, and our small data set is underpowered to
detect effects of HIV infection or undernutrition that could be clinically significant. A larger
study, or pooling of data, would help better characterise the effect of any of these important
covariates. Additionally, we did not detect an effect of formulation (whole tablets versus
crushed tablets versus suspension). The small sample size and confounding by age (young chil-
dren received suspension and older children whole tablets) limited our ability to detect such
formulation effects if they existed.
There were also limitations to our safety analysis. The modest number of children receiving
long-term linezolid and contributing to safety data limits the precision of our estimates of the
proportion of children with adverse events detected. The fact that more rare events, such as
optic neuropathy, were not detected does not mean they might not be observed with larger
numbers of patients. HIV-infected patients receiving linezolid may be at a higher risk of
adverse effects because of overlapping mitochondrial toxicity with some antiretroviral drugs,
especially the non-nucleoside reverse transcriptase inhibitors. This remains an important area
for future research.
Conclusion
This study provides urgently needed data on linezolid pharmacokinetics and prospective safety
data in children with TB. Linezolid exposures were higher than expected, and adverse events
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were common and occasionally severe. Based on these data, we have proposed, for the first
time, paediatric weight-banded doses approximating a 600-mg–daily adult linezolid dose.
Clear guidance on the optimal dose of linezolid for children with TB is urgently needed given
its growing importance in MDR-TB treatment regimens. These data have informed revised
WHO-recommended dosing in children.
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